The Record

The Orders Library

Name: The COVID Project Orders Library
Creator: The COVID Project

13,511 instruments indexed by The COVID Project: the orders of the fifty States and the District, forty metros, the federal layer and the agencies; the standing duties; the organizers' notices; the legal authorities. Filter by kind, State, limitation type, quarter and more; open the exhibit; download what you find.

Double quotes make a phrase ("stay at home"). An exhibit ID (TX-004) opens its record first.

The COVID Projectcovidproject.com/library

Filters:Kind: Order Agency cluster: Other federal health agencies From Mar. 6, 2020 Clear all

63 instruments · showing 1–25

Sort Per page

Exhibit	Instrument	Issuer	Jurisdiction	Issued	Quarters	Limitations	Grade
Ex. AGY-FED-HEALTH-OTHER-072	Federal Bureau of Prisons COVID-19 Action Plan, Phase Two: agency-wide modified operations (Mar. 13, 2020)Federal Bureau of Prisons COVID-19 Action Plan: Agency-wide Modified Operations	Federal Bureau of Prisons (Director), after coordination with DOJ and the White House	United States (federal); Federal Bureau of PrisonsFederal	Mar. 13, 2020	2020 Q2	Business closureGathering capTravel and quarantineWorkplace rules	Primary source read
Ex. AGY-FED-HEALTH-OTHER-008	DEA-DC-015, Exception to 21 C.F.R. 1301.74(h) for Narcotic Treatment Programs (take-home delivery by NTP staff, law enforcement or National Guard)SAMHSA Exemption - NTP Deliveries (Coronavirus)	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA (letter to Assistant Secretary Elinore McCance-Katz, SAMHSA)	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 16, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-009	DEA-DC-016, COVID-19 Information Page: Telemedicine (designation that the section 802(54)(D) telemedicine allowance applies to all schedule II-V controlled substances in all areas of the United States)Use of Telemedicine While Providing Medication Assisted Treatment / COVID-19 Telemedicine (updated)	Drug Enforcement Administration, Diversion Control Division (with the HHS Secretary's designation of Mar. 16, 2020)	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 16, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Telework mandateHealth care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-026	Opioid Treatment Program (OTP) Guidance (Mar. 16, 2020; updated Mar. 19, 2020): blanket take-home exceptionsOpioid Treatment Program (OTP) Guidance	SAMHSA (Assistant Secretary for Mental Health and Substance Use)	United States (federal); Substance Abuse and Mental Health Services AdministrationFederal	Mar. 16, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-001	Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency, 85 Fed. Reg. 22024 (Apr. 21, 2020)Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency	Roger T. Severino, Director, Office for Civil Rights, HHS	United States (federal); Department of Health and Human Services, Office for Civil RightsFederal	Mar. 17, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Telework mandateHealth care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-074	Updates to BOP COVID-19 Action Plan: Inmate Movement (Mar. 19, 2020)Updates to BOP COVID-19 Action Plan - Inmate Movement	Federal Bureau of Prisons	United States (federal); Federal Bureau of PrisonsFederal	Mar. 19, 2020	2020 Q2	Travel and quarantineQuarantine and isolation	Primary source read
Ex. AGY-FED-HEALTH-OTHER-010	DEA-DC-017 (DEA065), Dear Registrant letter on early refills and 90-day supplies of controlled substances during the COVID-19 emergencyEarly RX Refill (OMB 3-20-20)	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 20, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-012	DEA-DC-019 (DEA066), letter granting an exception permitting transmission of DEA Form 222 by fax or scan during the COVID-19 emergencyFax/Scan 222 (final) Esign	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA (letter to the Healthcare Distribution Alliance)	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 20, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Supply chainOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-036	Emergency Use Authorization Declaration (medical devices, including alternative products used as medical devices), 85 Fed. Reg. 17335 (Mar. 27, 2020)Emergency Use Authorization Declaration	Alex M. Azar II, Secretary of Health and Human Services	United States (federal); Department of Health and Human Services, Office of the SecretaryFederal	Mar. 24, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Emergency declarationSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-049	Emergency Use Authorization: Imported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators (issued Mar. 24, 2020; reissued Mar. 28, 2020, May 7, 2020 and Mar. 24, 2021; revoked July 6, 2021)Letter of Authorization, Imported Non-NIOSH-Approved Disposable Filtering Facepiece Respirators (reissued Mar. 24, 2021)	Denise M. Hinton, Chief Scientist, FDA	United States (federal); Food and Drug AdministrationFederal	Mar. 24, 2021	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-051	Emergency Use Authorization: Ventilators, anesthesia gas machines modified for use as ventilators, positive pressure breathing devices modified for use as ventilators, ventilator tubing connectors and ventilator accessories (Mar. 24, 2020)Letter of Authorization to Manufacturers and Other Stakeholders: Ventilators	Denise M. Hinton, Chief Scientist, FDA	United States (federal); Food and Drug AdministrationFederal	Mar. 24, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-011	DEA-DC-018 (DEA067), Dear Registrant letter granting an exception to separate State registration for practitioners dispensing in additional States during the COVID-19 emergencyDEA State Reciprocity (final) (Signed)	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 25, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Telework mandateHealth care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-131	Notice, Process for Making Available Guidance Documents Related to Coronavirus Disease 2019, 85 Fed. Reg. 16949 (Mar. 25, 2020)Process for Making Available Guidance Documents Related to Coronavirus Disease 2019	Food and Drug Administration, HHS	United States (federal); Food and Drug AdministrationFederal	Mar. 25, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Other	Primary source read
Ex. AGY-FED-HEALTH-OTHER-081	Memorandum for Director of Bureau of Prisons, Prioritization of Home Confinement As Appropriate in Response to COVID-19 Pandemic (Mar. 26, 2020)Prioritization of Home Confinement As Appropriate in Response to COVID-19 Pandemic	William P. Barr, Attorney General	United States (federal); Department of Justice, Office of the Attorney GeneralFederal	Mar. 26, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Other	Primary source read
Ex. AGY-FED-HEALTH-OTHER-013	DEA-DC-021 (DEA073), letter to practitioner registrants and pharmacists announcing temporary exceptions for oral schedule II prescriptions in emergency situations during the COVID-19 emergencyOral CII for regular CII script (Final)	Drug Enforcement Administration, Diversion Control Division	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 27, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-037	Emergency Use Authorization Declaration (drugs and biological products), 85 Fed. Reg. 18250 (Apr. 1, 2020)Emergency Use Authorization Declaration	Alex M. Azar II, Secretary of Health and Human Services	United States (federal); Department of Health and Human Services, Office of the SecretaryFederal	Mar. 27, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Emergency declarationSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-050	Emergency Use Authorization: Battelle Critical Care Decontamination System for decontaminating compatible N95 respirators (issued Mar. 28, 2020; reissued Jan. 21, 2021; revoked June 30, 2021)Letter of Authorization, Battelle CCDS Critical Care Decontamination System (reissued Jan. 21, 2021)	Denise M. Hinton, Chief Scientist, FDA (letter to Battelle Memorial Institute)	United States (federal); Food and Drug AdministrationFederal	Jan. 21, 2021	2020 Q22020 Q32020 Q42021 Q12021 Q2	Health care ordersSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-058	IHS Coronavirus (COVID-19) News page listing the Tribal and Urban Indian Organization Leader letters of Mar. 9, 16, 23 and 27, 2020 (archived Mar. 29, 2020)Coronavirus (COVID-19) / News: Tribal and Urban Indian Organization Leader Messages on COVID-19	Indian Health Service (Principal Deputy Director Rear Adm. Michael D. Weahkee)	United States (federal); Department of Health and Human Services, Indian Health ServiceFederal	Mar. 29, 2020	2020 Q2	Emergency declarationHealth care orders	Confirmed from a secondary source
Ex. AGY-FED-HEALTH-OTHER-014	DEA-DC-022 (DEA068), letter permitting DATA-waived practitioners to prescribe buprenorphine to new patients on the basis of a telephone evaluation during the COVID-19 emergencyDEA/SAMHSA Buprenorphine Telemedicine (Final)	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control Division (with SAMHSA)Federal	Mar. 31, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Telework mandateHealth care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-015	DEA-DC-023 (DEA075), How to Prescribe Controlled Substances to Patients During the COVID-19 Public Health Emergency (decision tree)How to Prescribe Controlled Substances to Patients During the COVID-19 Public Health Emergency	Drug Enforcement Administration, Diversion Control Division	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 31, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Telework mandateHealth care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-073	COVID-19 Action Plan: Phase Five (ordered Mar. 31, 2020; effective Apr. 1, 2020): inmates secured in assigned cells/quarters for 14 days; quarantine of new admissionsCOVID-19 Action Plan: Phase Five - Additional Agency-wide Actions Effective April 1	Director, Federal Bureau of Prisons	United States (federal); Federal Bureau of PrisonsFederal	Mar. 31, 2020	2020 Q2	Business closureGathering capQuarantine and isolation	Primary source read
Ex. AGY-FED-HEALTH-OTHER-002	Enforcement Discretion Under HIPAA To Allow Uses and Disclosures of Protected Health Information by Business Associates for Public Health and Health Oversight Activities in Response to COVID-19, 85 Fed. Reg. 19392 (Apr. 7, 2020)Enforcement Discretion Under HIPAA To Allow Uses and Disclosures of Protected Health Information by Business Associates for Public Health…	Roger T. Severino, Director, Office for Civil Rights, HHS	United States (federal); Department of Health and Human Services, Office for Civil RightsFederal	Apr. 2, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-082	Memorandum for Director of Bureau of Prisons, Increasing Use of Home Confinement at Institutions Most Affected by COVID-19 (Apr. 3, 2020)Increasing Use of Home Confinement at Institutions Most Affected by COVID-19	William P. Barr, Attorney General	United States (federal); Department of Justice, Office of the Attorney GeneralFederal	Apr. 3, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Emergency declarationOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-076	Update on COVID-19 and Home Confinement (Apr. 5, 2020)Update on COVID-19 and Home Confinement: BOP continuing to aggressively screen potential inmates	Federal Bureau of Prisons	United States (federal); Federal Bureau of PrisonsFederal	Apr. 5, 2020	2020 Q2	Other	Primary source read
Ex. AGY-FED-HEALTH-OTHER-016	DEA-DC-025 (DEA078), Dear Registrant letter permitting opioid treatment programs to use the same off-site location repeatedly to deliver take-home methadone doses without separate registrationOff-site OTP delivery method (Final)	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Apr. 7, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read

Federal Bureau of Prisons (Director), after coordination with DOJ and the White House, Federal Bureau of Prisons COVID-19 Action Plan, Phase Two: agency-wide modified operations (Mar. 13, 2020) (Ex. AGY-FED-HEALTH-OTHER-072)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA (letter to Assistant Secretary Elinore McCance-Katz, SAMHSA), DEA-DC-015, Exception to 21 C.F.R. 1301.74(h) for Narcotic Treatment Programs (take-home delivery by NTP staff, law enforcement or National Guard) (Mar. 16, 2020) (Ex. AGY-FED-HEALTH-OTHER-008)
Drug Enforcement Administration, Diversion Control Division (with the HHS Secretary's designation of Mar. 16, 2020), DEA-DC-016, COVID-19 Information Page: Telemedicine (designation that the section 802(54)(D) telemedicine allowance applies to all schedule II-V controlled substances in all areas of the United States) (Mar. 16, 2020) (Ex. AGY-FED-HEALTH-OTHER-009)
SAMHSA (Assistant Secretary for Mental Health and Substance Use), Opioid Treatment Program (OTP) Guidance (Mar. 16, 2020; updated Mar. 19, 2020): blanket take-home exceptions (Ex. AGY-FED-HEALTH-OTHER-026)
Roger T. Severino, Director, Office for Civil Rights, HHS, Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency, 85 Fed. Reg. 22024 (Apr. 21, 2020) (Mar. 17, 2020) (Ex. AGY-FED-HEALTH-OTHER-001)
Federal Bureau of Prisons, Updates to BOP COVID-19 Action Plan: Inmate Movement (Mar. 19, 2020) (Ex. AGY-FED-HEALTH-OTHER-074)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA, DEA-DC-017 (DEA065), Dear Registrant letter on early refills and 90-day supplies of controlled substances during the COVID-19 emergency (Mar. 20, 2020) (Ex. AGY-FED-HEALTH-OTHER-010)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA (letter to the Healthcare Distribution Alliance), DEA-DC-019 (DEA066), letter granting an exception permitting transmission of DEA Form 222 by fax or scan during the COVID-19 emergency (Mar. 20, 2020) (Ex. AGY-FED-HEALTH-OTHER-012)
Alex M. Azar II, Secretary of Health and Human Services, Emergency Use Authorization Declaration (medical devices, including alternative products used as medical devices), 85 Fed. Reg. 17335 (Mar. 27, 2020) (Mar. 24, 2020) (Ex. AGY-FED-HEALTH-OTHER-036)
Denise M. Hinton, Chief Scientist, FDA, Emergency Use Authorization: Imported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators (issued Mar. 24, 2020; reissued Mar. 28, 2020, May 7, 2020 and Mar. 24, 2021; revoked July 6, 2021) (Ex. AGY-FED-HEALTH-OTHER-049)
Denise M. Hinton, Chief Scientist, FDA, Emergency Use Authorization: Ventilators, anesthesia gas machines modified for use as ventilators, positive pressure breathing devices modified for use as ventilators, ventilator tubing connectors and ventilator accessories (Mar. 24, 2020) (Ex. AGY-FED-HEALTH-OTHER-051)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA, DEA-DC-018 (DEA067), Dear Registrant letter granting an exception to separate State registration for practitioners dispensing in additional States during the COVID-19 emergency (Mar. 25, 2020) (Ex. AGY-FED-HEALTH-OTHER-011)
Food and Drug Administration, HHS, Notice, Process for Making Available Guidance Documents Related to Coronavirus Disease 2019, 85 Fed. Reg. 16949 (Mar. 25, 2020) (Ex. AGY-FED-HEALTH-OTHER-131)
William P. Barr, Attorney General, Memorandum for Director of Bureau of Prisons, Prioritization of Home Confinement As Appropriate in Response to COVID-19 Pandemic (Mar. 26, 2020) (Ex. AGY-FED-HEALTH-OTHER-081)
Drug Enforcement Administration, Diversion Control Division, DEA-DC-021 (DEA073), letter to practitioner registrants and pharmacists announcing temporary exceptions for oral schedule II prescriptions in emergency situations during the COVID-19 emergency (Mar. 27, 2020) (Ex. AGY-FED-HEALTH-OTHER-013)
Alex M. Azar II, Secretary of Health and Human Services, Emergency Use Authorization Declaration (drugs and biological products), 85 Fed. Reg. 18250 (Apr. 1, 2020) (Mar. 27, 2020) (Ex. AGY-FED-HEALTH-OTHER-037)
Denise M. Hinton, Chief Scientist, FDA (letter to Battelle Memorial Institute), Emergency Use Authorization: Battelle Critical Care Decontamination System for decontaminating compatible N95 respirators (issued Mar. 28, 2020; reissued Jan. 21, 2021; revoked June 30, 2021) (Ex. AGY-FED-HEALTH-OTHER-050)
Indian Health Service (Principal Deputy Director Rear Adm. Michael D. Weahkee), IHS Coronavirus (COVID-19) News page listing the Tribal and Urban Indian Organization Leader letters of Mar. 9, 16, 23 and 27, 2020 (archived Mar. 29, 2020) (Ex. AGY-FED-HEALTH-OTHER-058)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA, DEA-DC-022 (DEA068), letter permitting DATA-waived practitioners to prescribe buprenorphine to new patients on the basis of a telephone evaluation during the COVID-19 emergency (Mar. 31, 2020) (Ex. AGY-FED-HEALTH-OTHER-014)
Drug Enforcement Administration, Diversion Control Division, DEA-DC-023 (DEA075), How to Prescribe Controlled Substances to Patients During the COVID-19 Public Health Emergency (decision tree) (Mar. 31, 2020) (Ex. AGY-FED-HEALTH-OTHER-015)
Director, Federal Bureau of Prisons, COVID-19 Action Plan: Phase Five (ordered Mar. 31, 2020; effective Apr. 1, 2020): inmates secured in assigned cells/quarters for 14 days; quarantine of new admissions (Ex. AGY-FED-HEALTH-OTHER-073)
Roger T. Severino, Director, Office for Civil Rights, HHS, Enforcement Discretion Under HIPAA To Allow Uses and Disclosures of Protected Health Information by Business Associates for Public Health and Health Oversight Activities in Response to COVID-19, 85 Fed. Reg. 19392 (Apr. 7, 2020) (Apr. 2, 2020) (Ex. AGY-FED-HEALTH-OTHER-002)
William P. Barr, Attorney General, Memorandum for Director of Bureau of Prisons, Increasing Use of Home Confinement at Institutions Most Affected by COVID-19 (Apr. 3, 2020) (Ex. AGY-FED-HEALTH-OTHER-082)
Federal Bureau of Prisons, Update on COVID-19 and Home Confinement (Apr. 5, 2020) (Ex. AGY-FED-HEALTH-OTHER-076)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA, DEA-DC-025 (DEA078), Dear Registrant letter permitting opioid treatment programs to use the same off-site location repeatedly to deliver take-home methadone doses without separate registration (Apr. 7, 2020) (Ex. AGY-FED-HEALTH-OTHER-016)

The Orders Library

Results